# Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS

> **NCT04257500** · PHASE4 · COMPLETED · sponsor: **Andrea Roe, MD, MPH** · enrollment: 22 (actual)

## Conditions studied

- Polycystic Ovary Syndrome

## Interventions

- **DRUG:** Etonogestrel/ethinyl estradiol vaginal ring

## Key facts

- **NCT ID:** NCT04257500
- **Lead sponsor:** Andrea Roe, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-03
- **Primary completion:** 2025-08-22
- **Final completion:** 2025-08-22
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04257500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04257500, "Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04257500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*